What is Phenomic AI?
Phenomic AI is a pioneering biotech firm dedicated to the development of novel therapies targeting solid tumors. Leveraging an advanced machine learning-powered single-cell transcriptomics platform, the company aims to revolutionize treatment outcomes for challenging cancers. By meticulously analyzing tumor biology, Phenomic AI identifies new drug targets, with its lead program focusing on a CD3 engager designed to overcome existing therapeutic limitations. The company actively engages in collaborations with major pharmaceutical entities to advance cancer treatment modalities, demonstrating a strong commitment to delivering innovative solutions for patients facing difficult-to-treat malignancies.
How much funding has Phenomic AI raised?
Phenomic AI has raised a total of $6M across 1 funding round:
Angel/Seed
$6M
Angel/Seed (2020): $6M with participation from Hike Ventures, Cantos Ventures, Garage Capital, Viva BioInnovator, Luminous Ventures, CTI Life Sciences Fund, and AV8 Ventures
Key Investors in Phenomic AI
Cantos Ventures
Cantos Ventures is a venture capital firm focused on investing in near frontier technology that aims to tackle some of the world's largest challenges, supporting technical founders and science-forward enterprises in fields including energy, aerospace, biomanufacturing, and digital health.
Garage Capital
Garage Technology Ventures, established in 1998, is an investment firm that focuses on helping startup companies invest and grow through creating their own solutions, with a presence in Palo Alto, California.
CTI Life Sciences Fund
CTI Life Sciences Fund is a Canadian venture capital firm specializing in biotech, focusing on catalyzing innovative ideas into scalable companies and has made over 30 investments in areas such as oncology and cardiology.
What's next for Phenomic AI?
The substantial enterprise-level funding and recent strategic investment indicate Phenomic AI is poised for significant scaling and further research and development. This capital infusion will likely accelerate the progression of its lead programs through clinical trials and expand its therapeutic pipeline. The company's strategic partnerships with established pharmaceutical players suggest a clear path toward commercialization and broader market penetration. Phenomic AI's focus on cutting-edge technology positions it as a key innovator in the oncology space, with future growth expected to be driven by continued scientific advancement and successful translation of its platform into effective patient treatments.
See full Phenomic AI company page
